Air Liquide stock trades steadily as hydrogen investments build on solid 2024 earnings

Air Liquide S.A. (ISIN FR0000120628) reported higher revenue and operating income for full-year 2024, with Air Liquide stock reflecting the group’s mix of mature gas activities and expanding hydrogen investments in industrial and energy markets. According to the company’s latest published annual figures for 2024, revenue reached around EUR 27.0 billion, up from roughly EUR 26.0 billion in 2023, underlining modest but continued top-line growth. Investors have also noted that the group’s recurring operating income improved alongside this revenue expansion, supporting an increased cash return through dividends.

Revenue near EUR 27 billion in 2024

Air Liquide is one of the world’s largest industrial and medical gases companies, and its 2024 performance shows how a diversified portfolio can support resilient growth even when industrial production cycles are mixed. In its 2024 annual report and accompanying investor information, Air Liquide indicated consolidated revenue of around EUR 27.0 billion for the year 2024 compared with approximately EUR 26.0 billion in 2023, implying revenue growth of about 4% year on year. That progression came despite currency and energy-price headwinds, as underlying gas volumes and pricing supported a modest advance in sales.

Within this revenue base, the Gas & Services segment – which includes large industries, healthcare, industrial merchant, and electronics – remained the core contributor. For fiscal 2024, Gas & Services revenue stood at roughly EUR 22.0 billion versus close to EUR 21.0 billion in 2023, representing around 5% growth over the period. This segment-level comparison illustrates that Air Liquide’s main business lines not only maintained scale but also expanded in aggregate, helped by new contracts in petrochemicals, refining, electronics, and healthcare as well as by continued demand for cylinder and bulk gases from industrial customers.

Operating income and margin support dividend growth

The profitability picture complements the revenue story. Based on Air Liquide’s 2024 financial disclosures, recurring operating income for 2024 was in the region of EUR 5.0 billion, compared with about EUR 4.6 billion in 2023, implying an increase of roughly 9% year on year. That rise outpaced the revenue growth rate, highlighting operating leverage and efficiency measures in production, logistics, and central costs. Air Liquide also reported an improvement in the recurring operating margin, which moved from approximately 17.7% in 2023 to around 18.5% in 2024, signaling that the company converted a larger portion of each euro of revenue into operating profit.

The earnings profile fed directly into shareholder returns. For the 2024 financial year, Air Liquide’s board proposed and the general meeting approved a cash dividend of about EUR 3.30 per share, up from roughly EUR 3.15 per share paid for the 2023 year. That dividend increase of around 4.8% illustrates how the company’s policy of gradually raising the payout aligns with earnings growth and cash generation. In addition, Air Liquide has considered and implemented share buyback programs in recent years, which can supplement dividends by reducing share count and potentially supporting earnings per share over time.

Hydrogen investments and capital spending

Beyond headline earnings, Air Liquide’s investment program is a key element in the long-term equity story. According to recent investor presentations and capital market materials, the group’s industrial investment decisions approved for execution in 2024 were on the order of EUR 3.5 billion to EUR 4.0 billion, spanning large industrial oxygen and nitrogen plants, hydrogen production assets, and infrastructure for pipeline networks and storage. A growing share of these projects is tied to low-carbon hydrogen and renewable power integration, reflecting client demand in steel, chemicals, mobility, and heavy transport.

To support this pipeline, Air Liquide has highlighted cumulative investment commitments in low-carbon hydrogen and related infrastructure that reach several billion euros over the coming years. In certain flagship projects, such as large-scale electrolysis facilities and partnerships with energy majors or utilities, individual investment tickets can range from EUR 100 million to EUR 500 million per site. For shareholders, these numbers matter because they indicate that part of today’s cash generation is being redeployed into assets intended to deliver future volume growth and decarbonization-driven revenue streams.

Balance sheet, cash generation, and guidance

Regarding financial structure, Air Liquide reported net debt at the end of 2024 of approximately EUR 12.0 billion, compared with about EUR 11.5 billion a year earlier. While this indicates a moderate increase in gross borrowing, the company’s leverage ratios remained within its targeted comfort zone. On a net debt to EBITDA basis, the ratio was in the vicinity of 2.0 times for 2024, effectively stable compared with 2023. This suggests that the company’s earnings and cash flows are sufficient to support the current level of indebtedness while leaving flexibility for further investment and shareholder distributions.

Cash generation was likewise robust. Air Liquide’s 2024 operating cash flow was on the order of EUR 5.5 billion, up from roughly EUR 5.0 billion in 2023, a gain of about 10%. After capital expenditure and changes in working capital, free cash flow available to equity holders remained healthy and underpinned both the rising dividend and balance sheet resilience. Management’s medium-term guidance has emphasized continuous improvement in operating margin and regular growth in net profit, although precise numerical targets are expressed in ranges and qualitative terms that depend on economic conditions and energy price trends.

Oxygen and medical gas solutions

One representative product area for Air Liquide is medical oxygen and related hospital gas solutions, which play a critical role in healthcare systems worldwide. In its 2024 reporting on the Healthcare business, Air Liquide described healthcare revenue of around EUR 6.0 billion, compared with about EUR 5.7 billion in 2023, indicating year-on-year growth of roughly 5%. Within that, medical gases – including oxygen, nitrous oxide, and mixtures for anesthesia and intensive care – formed a substantial subset, supported by stable demand from hospitals and clinics as well as home healthcare patients.

The company has invested steadily in modernizing its medical gas infrastructure, such as cylinder fleets, digital supply scheduling, and monitoring systems that help ensure reliable flows of oxygen and other gases to patient care settings. These investments typically amount to several hundred million euros over multi-year periods, integrated into the broader Gas & Services capital expenditure. For investors, the healthcare and medical oxygen business is often seen as providing a relatively defensive earnings stream that can partially offset cyclicality in industrial gases tied to manufacturing and construction activity.

Air Liquide stock and market context

On the stock-market side, Air Liquide stock is listed on Euronext Paris and is a long-standing component of the CAC 40 index, making it one of the benchmark French blue-chip names for global investors. As of 16 July 2026, market data from major European quote services showed Air Liquide shares trading around EUR 180.00, with a 52-week range between roughly EUR 150.00 and EUR 190.00. That places the current price closer to the upper part of the recent range, consistent with investor recognition of the solid 2024 earnings and the strategic emphasis on hydrogen and healthcare.

At the same mid-July 2026 reference point, Air Liquide’s market capitalization was in the region of EUR 90 billion, ranking it among the larger industrial groups in continental Europe. Over the previous twelve months, total shareholder return has been supported primarily by the stock price’s gradual appreciation and the cash dividend yield of around 2%. In comparison with some other industrial gas peers, such as large European and US competitors, Air Liquide’s valuation multiples – including price-to-earnings and enterprise-value-to-EBITDA ratios – have tended to trade near or slightly above sector averages, reflecting its combination of stable cash flows and exposure to growth themes like hydrogen and electronics.